Biotech recovery in Q3 2025 as venture funding grows 70.9% from Q2 2025
GlobalData’s Venture Capital Investment Trends In Pharma – Q3 2025 report revealed that the biotech industry witnessed a 70.9% increase…
GlobalData’s Venture Capital Investment Trends In Pharma – Q3 2025 report revealed that the biotech industry witnessed a 70.9% increase…
On Saturday 19 October 2025, at the European Society for Medical Oncology (ESMO), held in Berlin, Germany, Hengrui presented results…
At the 129th Annual Meeting of the American Academy of Ophthalmology (AAO) 2025 in Orlando, Florida, EyePoint Pharmaceuticals presented updates…
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results…
Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than…
Results from the Phase III registrational EV-303/KEYNOTE-905 study evaluating the combination of Pfizer’s and Astellas’ nectin-4 targeting antibody-drug conjugate Padcev…
Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m in the 2025's…
At the 2025 European Respiratory Society (ERS) International Congress taking place in Amsterdam, the Netherlands, from 27 September to 1…
At the 2025 European Respiratory Society (ERS) International Congress takig place in Amsterdam, the Netherlands, from 27 September to 1…
On 15 August 2025, Novo Nordisk’s Wegovy (semaglutide 2.4mg) received accelerated approval from the US Food and Drug Administration for…